APELLIS PHARMACEUTICALS, INC.
6400 Westwind Way, Suite A
Crestwood, KY 40014
November 6, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Apellis Pharmaceuticals, Inc. |
| Registration Statement on Form S-1 |
| File No. 333-220941 |
| Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Apellis Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-220941), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on November 8, 2017, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
* * * *
| Very truly yours,
| ||
| APELLIS PHARMACEUTICALS, INC. | ||
| By: | /s/ David Watson | |
| Name: |
David Watson | |
| Title: |
General Counsel | |
| cc: | Cedric Francois, Apellis Pharmaceuticals, Inc. |
| Stuart M. Falber, Wilmer Cutler Pickering Hale and Dorr LLP |
| Brent B. Siler, Cooley LLP |
| Darren DeStefano, Cooley LLP |
| Divakar Gupta, Cooley LLP |
| Mark Ballantyne, Cooley LLP |